{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:11:09Z","timestamp":1793045469402,"version":"4.5.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T00:00:00Z","timestamp":1752105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","award":["Qiankehe Support [2021] General 049"],"award-info":[{"award-number":["Qiankehe Support [2021] General 049"]}],"id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018555","name":"Science and Technology Program of Guizhou Province","doi-asserted-by":"publisher","award":["Qiankehe Platform Talent-CXTD[2023]028"],"award-info":[{"award-number":["Qiankehe Platform Talent-CXTD[2023]028"]}],"id":[{"id":"10.13039\/501100018555","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40121-025-01189-0","type":"journal-article","created":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T10:04:18Z","timestamp":1752141858000},"page":"1599-1617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Impact of Metabolic Dysfunction-Associated Fatty Liver Disease of Varying Severity on Antiviral Treatment Outcomes and Clinical Prognosis in Patients with Chronic Hepatitis B: A Systematic Review and Meta-analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Qianqian","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengde","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingdan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yali","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuxiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawen","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"17","key":"1189_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1097\/cm9.0000000000002331","volume":"135","author":"G Cao","year":"2022","unstructured":"Cao G, Liu J, Liu M. Trends in mortality of liver disease due to hepatitis B in China from 1990 to 2019: findings from the Global Burden of Disease Study. Chin Med J (Engl). 2022;135(17):2049\u201355. https:\/\/doi.org\/10.1097\/cm9.0000000000002331.","journal-title":"Chin Med J (Engl)"},{"key":"1189_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101193","volume":"51","author":"Z Hui","year":"2024","unstructured":"Hui Z, Yu W, Fuzhen W, Liping S, Guomin Z, Jianhua L, et al. New progress in HBV control and the cascade of health care for people living with HBV in China: evidence from the fourth national serological survey, 2020. Lancet Reg Health West Pac. 2024;51: 101193. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101193.","journal-title":"Lancet Reg Health West Pac"},{"issue":"02","key":"1189_CR3","first-page":"205","volume":"41","author":"S Dan","year":"2025","unstructured":"Dan S, Jia J. Progress and challenges in the treatment of chronic hepatitis B in China. J Clin Hepatol. 2025;41(02):205\u20139.","journal-title":"J Clin Hepatol"},{"issue":"1","key":"1189_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28436","volume":"95","author":"A Kar","year":"2023","unstructured":"Kar A, Samanta A, Mukherjee S, Barik S, Biswas A. The HBV web: An insight into molecular interactomes between the hepatitis B virus and its host en route to hepatocellular carcinoma. J Med Virol. 2023;95(1): e28436. https:\/\/doi.org\/10.1002\/jmv.28436.","journal-title":"J Med Virol"},{"issue":"2","key":"1189_CR5","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80(2):e54\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021.","journal-title":"J Hepatol"},{"issue":"1","key":"1189_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101155","volume":"29","author":"R Yao","year":"2024","unstructured":"Yao R, Lu S, Xue R, Wang J, Qiu Y, Chen Y, et al. NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: a multi-center, retrospective study. Ann Hepatol. 2024;29(1): 101155. https:\/\/doi.org\/10.1016\/j.aohep.2023.101155.","journal-title":"Ann Hepatol"},{"issue":"5","key":"1189_CR7","first-page":"513","volume":"9","author":"MM Fu","year":"2010","unstructured":"Fu MM, Sun R, Tian ZG, Wei HM. Increased susceptibility to experimental steatohepatitis induced by methionine-choline deficiency in HBs-Tg mice. Hepatobiliary Pancreat Dis Int. 2010;9(5):513\u20139.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"4","key":"1189_CR8","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1016\/j.jhep.2020.05.040","volume":"73","author":"LY Mak","year":"2020","unstructured":"Mak LY, Hui RW, Fung J, Liu F, Wong DK, Cheung KS, et al. Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B. J Hepatol. 2020;73(4):800\u20136. https:\/\/doi.org\/10.1016\/j.jhep.2020.05.040.","journal-title":"J Hepatol"},{"issue":"11","key":"1189_CR9","doi-asserted-by":"publisher","first-page":"2481","DOI":"10.1007\/s11010-021-04143-z","volume":"477","author":"Q Liu","year":"2022","unstructured":"Liu Q, Mu M, Chen H, Zhang G, Yang Y, Chu J, et al. Hepatocyte steatosis inhibits hepatitis B virus secretion via induction of endoplasmic reticulum stress. Mol Cell Biochem. 2022;477(11):2481\u201391. https:\/\/doi.org\/10.1007\/s11010-021-04143-z.","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"1189_CR10","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3350\/cmh.2023.0004","volume":"29","author":"YJ Wong","year":"2023","unstructured":"Wong YJ, Nguyen VH, Yang HI, Li J, Le MH, Wu WJ, et al. Impact of fatty liver on long-term outcomes in chronic hepatitis B: a systematic review and matched analysis of individual patient data meta-analysis. Clin Mol Hepatol. 2023;29(3):705\u201320. https:\/\/doi.org\/10.3350\/cmh.2023.0004.","journal-title":"Clin Mol Hepatol"},{"issue":"9","key":"1189_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle\u2013Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"issue":"04","key":"1189_CR12","first-page":"297","volume":"4","author":"X Zeng","year":"2012","unstructured":"Zeng X, Liu H, Chen Xi, Leng W. Series on meta-analysis IV: quality assessment tools for observational studies. Chin J Evid Based Cardiovasc Med. 2012;4(04):297\u20139.","journal-title":"Chin J Evid Based Cardiovasc Med"},{"key":"1189_CR13","doi-asserted-by":"publisher","first-page":"117863612091887","DOI":"10.1177\/1178636120918878","volume":"13","author":"CT Lim","year":"2020","unstructured":"Lim CT, Goh GBB, Li H, Lim TK, Leow WQ, Wan WK, et al. Presence of hepatic steatosis does not increase the risk of hepatocellular carcinoma in patients with chronic hepatitis B over long follow-up. Microbiol Insights. 2020;13:1178636120918878. https:\/\/doi.org\/10.1177\/1178636120918878.","journal-title":"Microbiol Insights"},{"issue":"2","key":"1189_CR14","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1002\/hep.30857","volume":"71","author":"HSJ Choi","year":"2020","unstructured":"Choi HSJ, Brouwer WP, Zanjir WMR, de Man RA, Feld JJ, Hansen BE, et al. Nonalcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B. Hepatology. 2020;71(2):539\u201348. https:\/\/doi.org\/10.1002\/hep.30857.","journal-title":"Hepatology"},{"issue":"1","key":"1189_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.gastha.2021.09.005","volume":"1","author":"HH Ko","year":"2022","unstructured":"Ko HH, Patel NH, Haylock-Jacobs S, Doucette K, Ma MM, Cooper C, et al. Severe hepatic steatosis is associated with low-level viremia and advanced fibrosis in patients with chronic hepatitis B in North America. Gastro Hep Adv. 2022;1(1):106\u201316.","journal-title":"Gastro Hep Adv"},{"issue":"12","key":"1189_CR16","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1111\/hepr.13830","volume":"52","author":"B Yun","year":"2022","unstructured":"Yun B, Ahn SH, Oh J, Yoon JH, Kim BK. Effect of metabolic dysfunction-associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: a nationwide study. Hepatol Res. 2022;52(12):975\u201384. https:\/\/doi.org\/10.1111\/hepr.13830.","journal-title":"Hepatol Res"},{"issue":"5","key":"1189_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100350","volume":"3","author":"LA van Kleef","year":"2021","unstructured":"van Kleef LA, Choi HSJ, Brouwer WP, Hansen BE, Patel K, de Man RA, et al. Metabolic dysfunction-associated fatty liver disease increases risk of adverse outcomes in patients with chronic hepatitis B. JHEP Rep. 2021;3(5): 100350. https:\/\/doi.org\/10.1016\/j.jhepr.2021.100350.","journal-title":"JHEP Rep"},{"key":"1189_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14236012","author":"MW Yu","year":"2022","unstructured":"Yu MW, Lin CL, Liu CJ, Wu WJ, Hu JT, Huang YW. Metabolic-associated fatty liver disease, hepatitis B surface antigen seroclearance, and long-term risk of hepatocellular carcinoma in chronic hepatitis B. Cancers (Basel). 2022. https:\/\/doi.org\/10.3390\/cancers14236012.","journal-title":"Cancers (Basel)."},{"issue":"1","key":"1189_CR19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jhepr.2019.02.002","volume":"1","author":"N Peleg","year":"2019","unstructured":"Peleg N, Issachar A, Sneh Arbib O, Cohen-Naftaly M, Braun M, Leshno M, et al. Liver steatosis is a strong predictor of mortality and cancer in chronic hepatitis B regardless of viral load. JHEP Rep. 2019;1(1):9\u201316. https:\/\/doi.org\/10.1016\/j.jhepr.2019.02.002.","journal-title":"JHEP Rep"},{"issue":"5","key":"1189_CR20","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s12072-023-10545-6","volume":"17","author":"SC Huang","year":"2023","unstructured":"Huang SC, Su TH, Tseng TC, Chen CL, Hsu SJ, Liao SH, et al. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. Hepatol Int. 2023;17(5):1139\u201349. https:\/\/doi.org\/10.1007\/s12072-023-10545-6.","journal-title":"Hepatol Int"},{"issue":"1","key":"1189_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3350\/cmh.2018.0040","volume":"25","author":"YB Lee","year":"2019","unstructured":"Lee YB, Ha Y, Chon YE, Kim MN, Lee JH, Park H, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol. 2019;25(1):52\u201364. https:\/\/doi.org\/10.3350\/cmh.2018.0040.","journal-title":"Clin Mol Hepatol"},{"key":"1189_CR22","unstructured":"Boshi C. The impact of nonalcoholic fatty liver disease on liver-related adverse events in chronic hepatitis B [Master\u2019s thesis]. 2023."},{"issue":"04","key":"1189_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.16505\/j.2095-0136.2021.0025","volume":"11","author":"F Chen","year":"2021","unstructured":"Chen F, Huang W, Li X, Qing L, Liu Y. Histological analysis of liver tissues in patients with chronic hepatitis B and nonalcoholic fatty liver disease. Chin J Viral Dis. 2021;11(04):261\u20135. https:\/\/doi.org\/10.16505\/j.2095-0136.2021.0025.","journal-title":"Chin J Viral Dis"},{"key":"1189_CR24","unstructured":"Yan J. Clinical characteristics and pathological changes in patients with chronic hepatitis B and hepatic steatosis [Master\u2019s thesis]. 2017."},{"key":"1189_CR25","unstructured":"Na L. Impact of hepatic steatosis on the clinical prognosis of patients with chronic hepatitis B [Master\u2019s thesis]. 2022."},{"issue":"10","key":"1189_CR26","first-page":"2230","volume":"38","author":"W Liu","year":"2022","unstructured":"Liu W, Liu H, Ding H, Li L. Clinical characteristics and prognostic factors in chronic hepatitis B with metabolic-associated fatty liver disease. J Clin Hepatol. 2022;38(10):2230\u20135.","journal-title":"J Clin Hepatol"},{"issue":"07","key":"1189_CR27","first-page":"1343","volume":"40","author":"L L\u00fc","year":"2024","unstructured":"L\u00fc L, Li Qi, Ma W, Ding H, Liu H. Stratified analysis of virological features in patients with chronic hepatitis B and metabolic-associated fatty liver disease. J Clin Hepatol. 2024;40(07):1343\u20138.","journal-title":"J Clin Hepatol"},{"issue":"10","key":"1189_CR28","first-page":"899","volume":"34","author":"Ou Shuangyu","year":"2024","unstructured":"Shuangyu Ou, Tang B, Li W, Zhong W. Predictive efficiency and correlation of serological virology and liver fibrosis staging in chronic hepatitis B patients with hepatic steatosis. J Liver Dis Integr Tradit Chin West Med. 2024;34(10):899\u2013902.","journal-title":"J Liver Dis Integr Tradit Chin West Med"},{"issue":"03","key":"1189_CR29","first-page":"256","volume":"12","author":"F Xie","year":"2018","unstructured":"Xie F, Meng Q, Hou W, Chen D. Clinical and pathological characteristics of HBeAg-positive chronic hepatitis B patients with nonalcoholic fatty liver disease. Chin J Exp Clin Infect Dis (Electronic Edition). 2018;12(03):256\u201361.","journal-title":"Chin J Exp Clin Infect Dis (Electronic Edition)"},{"key":"1189_CR30","unstructured":"Hengyi D. Observation on the efficacy of entecavir in the treatment of HBeAg-positive chronic hepatitis B with nonalcoholic fatty liver disease [Master\u2019s thesis]. 2023."},{"issue":"33","key":"1189_CR31","first-page":"101","volume":"27","author":"B Han","year":"2021","unstructured":"Han B, Zhang J, Liu W. Analysis of the effect of fatty liver on the antiviral efficacy of adefovir dipivoxil in chronic hepatitis B. Contemp Med. 2021;27(33):101\u20133.","journal-title":"Contemp Med"},{"issue":"03","key":"1189_CR32","first-page":"329","volume":"23","author":"Lu Jianguo","year":"2014","unstructured":"Jianguo Lu. Clinical efficacy of pegylated interferon alpha-2a in the treatment of chronic hepatitis B with fatty liver. J Gastroenterol Hepatol. 2014;23(03):329\u201332.","journal-title":"J Gastroenterol Hepatol"},{"issue":"05","key":"1189_CR33","first-page":"849","volume":"33","author":"Wu Yanqin","year":"2017","unstructured":"Yanqin Wu, Shen L, Jihong Yu, Sun Y. Evaluation of the effect of entecavir in the treatment of chronic hepatitis B with hepatic steatosis. J Clin Hepatol. 2017;33(05):849\u201352.","journal-title":"J Clin Hepatol"},{"issue":"10","key":"1189_CR34","doi-asserted-by":"publisher","first-page":"48","DOI":"10.14163\/j.cnki.11-5547\/r.2019.10.022","volume":"14","author":"Yu Zhongsheng","year":"2019","unstructured":"Zhongsheng Yu, Zhou B, Tang D, Liu S. Study on the impact of hepatic steatosis on the antiviral effect in chronic hepatitis B. Chin Pract Med. 2019;14(10):48\u20139. https:\/\/doi.org\/10.14163\/j.cnki.11-5547\/r.2019.10.022.","journal-title":"Chin Pract Med"},{"issue":"01","key":"1189_CR35","first-page":"250","volume":"9","author":"Yu Bingbing","year":"2019","unstructured":"Bingbing Yu, Zhang L, Chen Z, Zhong Y. Effect of entecavir antiviral therapy in chronic hepatitis B patients with hepatic steatosis. Chin Med Sci. 2019;9(01):250\u20132.","journal-title":"Chin Med Sci"},{"issue":"09","key":"1189_CR36","doi-asserted-by":"publisher","first-page":"692","DOI":"10.14000\/j.cnki.issn.1008-1704.2014.09.015","volume":"19","author":"W Zhang","year":"2014","unstructured":"Zhang W, Jianguo Yu, Zhu G, Zhao Z, Wang X. Effect of fatty liver and related factors on the efficacy of pegylated interferon alpha-2a in the treatment of chronic hepatitis B. Liver. 2014;19(09):692\u20134. https:\/\/doi.org\/10.14000\/j.cnki.issn.1008-1704.2014.09.015.","journal-title":"Liver"},{"issue":"03","key":"1189_CR37","first-page":"256","volume":"12","author":"X Fang","year":"2018","unstructured":"Fang X, Qinghua M, Wei H, Dexi C, Qing HM, Wei H, et al. Clinical and pathological features of HBeAg-positive chronic hepatitis B patients with nonalcoholic fatty liver disease. Chin J Exp Clin Infect Dis (Electronic Edition). 2018;12(03):256\u201361.","journal-title":"Chin J Exp Clin Infect Dis (Electronic Edition)."},{"key":"1189_CR38","unstructured":"Guidelines for the prevention and treatment of chronic hepatitis B (2010 Edition). Chin J Hepatol. 2011(01):13\u201324"},{"key":"1189_CR39","unstructured":"Fatty Liver and Alcoholic Liver Disease Group, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for diagnosis and treatment of nonalcoholic fatty liver disease (2010 Revision). Chin J Hepatol. 2010;18(03):163\u2013166"},{"key":"1189_CR40","unstructured":"Chinese Society of Infectious Diseases, Chinese Society of Hepatology. Guidelines for the prevention and treatment of chronic hepatitis B. Chin J Hepatol. 2005(12):881\u2013891"},{"key":"1189_CR41","unstructured":"Fatty Liver and Alcoholic Liver Disease Group, Chinese Society of Hepatology. Guidelines for diagnosis and treatment of nonalcoholic fatty liver disease. Chin J Hepatol. 2006(03):161\u2013163"},{"key":"1189_CR42","unstructured":"Chinese Society of Infectious Diseases, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (2019 Edition). Chin J Hepatol. 2019(12):938\u2013961"},{"key":"1189_CR43","unstructured":"Fatty Liver and Alcoholic Liver Disease Group, Chinese Society of Hepatology, Fatty Liver Disease Expert Committee of Chinese Medical Doctor Association. Guidelines for the prevention and treatment of nonalcoholic fatty liver disease (2018 Update). Chin J Hepatol. 2018(03):195\u2013203"},{"issue":"10","key":"1189_CR44","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1111\/jvh.13872","volume":"30","author":"R Zhou","year":"2023","unstructured":"Zhou R, Yang L, Zhang B, Gu Y, Kong T, Zhang W, et al. Clinical impact of hepatic steatosis on chronic hepatitis B patients in Asia: a systematic review and meta-analysis. J Viral Hepat. 2023;30(10):793\u2013802. https:\/\/doi.org\/10.1111\/jvh.13872.","journal-title":"J Viral Hepat"},{"issue":"5","key":"1189_CR45","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1002\/hep.32792","volume":"77","author":"X Mao","year":"2023","unstructured":"Mao X, Cheung KS, Peng C, Mak LY, Cheng HM, Fung J, et al. Steatosis, HBV-related HCC, cirrhosis, and HBsAg seroclearance: a systematic review and meta-analysis. Hepatology. 2023;77(5):1735\u201345. https:\/\/doi.org\/10.1002\/hep.32792.","journal-title":"Hepatology"},{"issue":"5","key":"1189_CR46","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/sj.ijo.0803479","volume":"31","author":"CM Chu","year":"2007","unstructured":"Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond). 2007;31(5):871\u20135. https:\/\/doi.org\/10.1038\/sj.ijo.0803479.","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"1189_CR47","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1002\/hep.28917","volume":"65","author":"EJ Joo","year":"2017","unstructured":"Joo EJ, Chang Y, Yeom JS, Ryu S. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: a cohort study. Hepatology. 2017;65(3):828\u201335. https:\/\/doi.org\/10.1002\/hep.28917.","journal-title":"Hepatology"},{"issue":"6","key":"1189_CR48","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15(6):349\u201364. https:\/\/doi.org\/10.1038\/s41575-018-0009-6.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"1189_CR49","doi-asserted-by":"publisher","DOI":"10.5812\/hepatmon.15(5)2015.27909","volume":"15","author":"RN Zhang","year":"2015","unstructured":"Zhang RN, Pan Q, Zhang Z, Cao HX, Shen F, Fan JG. Saturated fatty acid inhibits viral replication in chronic hepatitis B virus infection with nonalcoholic Fatty liver disease by toll-like receptor 4-mediated innate immune response. Hepat Mon. 2015;15(5): e27909. https:\/\/doi.org\/10.5812\/hepatmon.15(5)2015.27909.","journal-title":"Hepat Mon"},{"issue":"7","key":"1189_CR50","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/jvh.13942","volume":"31","author":"F Rui","year":"2024","unstructured":"Rui F, Garcia E, Hu X, Ni W, Xue Q, Xu Y, et al. Antiviral therapy response in patients with chronic hepatitis B and fatty liver: a systematic review and meta-analysis. J Viral Hepat. 2024;31(7):372\u201382. https:\/\/doi.org\/10.1111\/jvh.13942.","journal-title":"J Viral Hepat"},{"issue":"2","key":"1189_CR51","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4291\/wjgp.v7.i2.235","volume":"7","author":"N Kurabe","year":"2016","unstructured":"Kurabe N, Igarashi H, Ohnishi I, Tajima S, Inoue Y, Takahashi Y, et al. Visualization of sphingolipids and phospholipids in the fundic gland mucosa of human stomach using imaging mass spectrometry. World J Gastrointest Pathophysiol. 2016;7(2):235\u201341. https:\/\/doi.org\/10.4291\/wjgp.v7.i2.235.","journal-title":"World J Gastrointest Pathophysiol"},{"issue":"1","key":"1189_CR52","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11427-023-2561-0","volume":"68","author":"F Sun","year":"2025","unstructured":"Sun F, Li H, Sun D, Fu S, Gu L, Shao X, et al. Single-cell omics: experimental workflow, data analyses and applications. Sci China Life Sci. 2025;68(1):5\u2013102. https:\/\/doi.org\/10.1007\/s11427-023-2561-0.","journal-title":"Sci China Life Sci"},{"issue":"10","key":"1189_CR53","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.13345\/j.cjb.200112","volume":"36","author":"H Tian","year":"2020","unstructured":"Tian H, Yang Z, Xu X, Liu L. Three-dimensional chromosome conformation capture and its derived technologies. Sheng Wu Gong Cheng Xue Bao. 2020;36(10):2040\u201350. https:\/\/doi.org\/10.13345\/j.cjb.200112.","journal-title":"Sheng Wu Gong Cheng Xue Bao"},{"issue":"1","key":"1189_CR54","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s40121-022-00725-6","volume":"12","author":"Y Diao","year":"2023","unstructured":"Diao Y, Tang J, Wang X, Deng W, Tang J, You C. Metabolic syndrome, nonalcoholic fatty liver disease, and chronic hepatitis B: a narrative review. Infect Dis Ther. 2023;12(1):53\u201366. https:\/\/doi.org\/10.1007\/s40121-022-00725-6.","journal-title":"Infect Dis Ther"},{"issue":"8","key":"1189_CR55","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.14309\/ajg.0000000000001257","volume":"116","author":"M Khalili","year":"2021","unstructured":"Khalili M, Kleiner DE, King WC, Sterling RK, Ghany MG, Chung RT, et al. Hepatic steatosis and steatohepatitis in a large North American cohort of adults with chronic hepatitis B. Am J Gastroenterol. 2021;116(8):1686\u201397. https:\/\/doi.org\/10.14309\/ajg.0000000000001257.","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"1189_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2023.113721","volume":"430","author":"Y Lu","year":"2023","unstructured":"Lu Y, Yang X, Kuang Q, Wu Y, Tan X, Lan J, et al. HBx induced upregulation of FATP2 promotes the development of hepatic lipid accumulation. Exp Cell Res. 2023;430(1): 113721. https:\/\/doi.org\/10.1016\/j.yexcr.2023.113721.","journal-title":"Exp Cell Res"},{"key":"1189_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.636897","volume":"12","author":"J Zhang","year":"2021","unstructured":"Zhang J, Ling N, Lei Y, Peng M, Hu P, Chen M. Multifaceted interaction between hepatitis B virus infection and lipid metabolism in hepatocytes: a potential target of antiviral therapy for chronic hepatitis B. Front Microbiol. 2021;12: 636897. https:\/\/doi.org\/10.3389\/fmicb.2021.636897.","journal-title":"Front Microbiol"},{"key":"1189_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081917","author":"S Mukherjee","year":"2021","unstructured":"Mukherjee S, Kar A, Khatun N, Datta P, Biswas A, Barik S. Familiarity breeds strategy: in silico untangling of the molecular complexity on course of autoimmune liver disease-to-hepatocellular carcinoma transition predicts novel transcriptional signatures. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10081917.","journal-title":"Cells"},{"issue":"26","key":"1189_CR59","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.3748\/wjg.v27.i26.3971","volume":"27","author":"YW Shi","year":"2021","unstructured":"Shi YW, Yang RX, Fan JG. Chronic hepatitis B infection with concomitant hepatic steatosis: current evidence and opinion. World J Gastroenterol. 2021;27(26):3971\u201383. https:\/\/doi.org\/10.3748\/wjg.v27.i26.3971.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"1189_CR60","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","volume":"160","author":"ZM Younossi","year":"2021","unstructured":"Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review. Gastroenterology. 2021;160(3):912\u20138. https:\/\/doi.org\/10.1053\/j.gastro.2020.11.051.","journal-title":"Gastroenterology"},{"key":"1189_CR61","doi-asserted-by":"publisher","first-page":"1137084","DOI":"10.3389\/fmicb.2023.1137084","volume":"14","author":"DH Kim","year":"2023","unstructured":"Kim DH, Choi YM, Jang J, Kim BJ. Global prevalence and molecular characteristics of three clades within hepatitis B virus subgenotype C2: predominance of the C2(3) clade in South Korea. Front Microbiol. 2023;14:1137084. https:\/\/doi.org\/10.3389\/fmicb.2023.1137084.","journal-title":"Front Microbiol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01189-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01189-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T04:15:57Z","timestamp":1757218557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01189-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1189"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01189-0","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,10]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Qianqian Zhu: Chengde Su: Mingdan Li: Yali Xu, Qian Liu, Ying Zhang, Xinyi Zhang, Qiuxiang Li, Huajun Wang, Yawen Luo, Yawen Luo, Ping Yang declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}